In the race against drug-resistant bacteria, the emergence of new antibiotics marks a pivotal moment in modern medicine.Kinvard Bio, a groundbreaking Harvard startup, is at the forefront of this battle by developing innovative compounds known as oxepanoprolinamides that show exceptional potential against antimicrobial resistance.